AiCuris Anti-infective Cures AG - Clear Focus on Anti-Infective Cures

2022-11-29

Biofit Conference 2022, November 29-30, 2022, Strasbourg, France

AiCuris corporate incubator, to apply for the resident status or looking for a partnering opportunity in an anti-infective field – meet us at the conference

2022-11-17

Pharma partnering Summit US 2022, November 17-18, 2022, Boston, USA

AiCuris will participate at Bio Europe 2022 conference.

2022-10-24

AiCuris’ Licensing Partner MSD Demonstrates Efficacy in Phase 3 Study with PREVYMIS® for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation

In late breaking presentation at IDweek MSD reported positive findings from a phase 3 clinical trial that met the primary endpoint. With a superior safety profile PREVYMIS (letermovir) was shown to be effective and non-inferior to standard of care, valganciclovir, for preventing CMV disease in adult kidney transplant recipients. Based on these findings, MSD plans to submit a sNDA to the FDA by the end of this year. “We are excited that our partner MSD built on the initial success of PREVYMIS in the hematological transplant setting,” said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures AG. “This important milestone further validates our ability to successfully develop innovative therapies that have the potential to truly make a difference for patients suffering from serious infectious diseases.”

2022-09-29

AiCuris´ innovation accelerator AiCubator calls for innovative proposals to propel anti-infective drug development in the third round

AiCuris´ innovation accelerator AiCubator calls for innovative proposals to propel anti-infective drug development in the third round. AiCuris announced the opening of the third round of its AiCubator, a corporate innovation accelerator initiative. The AiCubator accelerator program was launched to provide first-hand support to fuel early research projects from young start-ups and academic teams with the potential to become the next generation resistance breaking anti-infective therapy. “At AiCuris, we strongly believe there is a need to nurture groundbreaking ideas in a very early stage to fill pipeline gaps and combat AMR and prevent pandemics,” said Dr. Holger Zimmermann, CEO of AiCuris.

2022-09-08

AiCuris nominates team of researchers from the Universitätsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative

AiCuris´s corporate innovation accelerator AiCubator has been strengthened by a novel collaboration with researchers from the Universitätsklinikum Erlangen. Prof. Dr. Manfred Marschall and his team from the Institute for Clinical and Molecular Virology Universitätsklinikum Erlangen, (Medical Center of the Friedrich-Alexander University of Erlangen-Nürnberg, Germany) have been awarded AiCubator Resident Status. The team identified a novel target that might be relevant for the treatment of herpesvirus infections.

2022-09-01

AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer

“It is my pleasure to welcome Dr. Sabrina Kuttruff-Coqui as our new CFO. With her proven track record in financial transactions, strategy and product development, as well as her commitment to sustainable value creation, she is an ideal match for our executive team at AiCuris,” said Dr. Stefan Oschmann, Chairman of the Board of AiCuris.

2022-04-14

AiCuris is opening first study centers in Germany for its international pivotal phase 3 trial with pritelivir for the treatment of herpes simplex virus infections in immunocompromised patients

Immunocompromised patients with aciclovir-resistant herpes simplex virus (HSV) infections can now participate in one of the renowned medical centers, Munich Klinikum Neuperlach or III. Medical Clinic of the University Medicine Mannheim (UMM), in the pivotal phase 3 trial with the drug candidate Pritelivir (AIC316), a novel helicase-primase inhibitor, developed by AiCuris. The trial is designed to evaluate the efficacy and safety of oral pritelivir compared to standard intravenous foscarnet therapy. Press release in German - Pressemitteilung in Deutsch

2022-04-08

AiCuris nominates Madam Therapeutics with its innovative peptide approach to fight AMR as the first winner of the AiCubator Resident Status in 2022, a corporate innovation accelerator initiative at BIOCOM AMR Conference 2022

In its second year an innovative artificial intelligence-based approach to fight antimicrobial resistance with dual-acting antimicrobial and antibiofilm peptides from Madam Therapeutics was selected to join the AiCubator initiative as the first new Resident in 2022. AiCubator” was launched by AiCuris mid-2020 to provide long-term support for early but promising research projects in the field of anti-infectives

2022-03-03

AiCuris receives NRW funding of EUR 5.9 million for the development of its corona virus program to prevent severe symptoms of SARS-CoV-2 infections

AiCuris receives NRW funding of EUR 5.9 million for the development of its corona virus program to prevent severe symptoms of SARS-CoV-2 infections NRW Economics and Innovation Minister Prof. Andreas Pinkwart visited AiCuris Anti-infective Cures AG with good news. Funding of EUR 5.9 million from the Ministry of Economics, Innovation, Digitization and Energy of the State of North Rhine-Westphalia is intended to advance the development of AiCuris' immune modulator AIC649 for the treatment of COVID-19 patients. “The keyword is “pandemic preparedness”. Our drug has the potential to form a protective wall - also against future viruses," said AiCuris CEO Holger Zimmermann. (press release only in German)

2022-02-09

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

AiCuris and Hybridize Therapeutics enter worldwide license agreement for a direct-acting RNA-based therapy against BK Virus. “This exciting novel approach further strengthens our anti-infective pipeline and builds on our strong track record in the field of infectious diseases. If shown to be safe and effective, it could be a true game changer in transplantation medicine with the potential to prevent kidney transplant patients from developing graft rejection and organ loss due to BKV,” said AiCuris CEO Holger Zimmermann.

2021-10-22

AiCuris announces expansion of its collaboration with Lysando with a focus on diabetic foot infections

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, and the biotechnology company Lysando AG with its Regensburg-based subsidiary Lysando GmbH, today announced the expansion of their existing long-term collaboration for the development and optimization of Artilysin®-based drug candidates for the topical treatment of infected, chronic wounds such as diabetic foot infections.

2021-10-07

AiCuris announces opening of second round of AiCubator corporate innovation accelerator initiative to propel anti-infective drug development

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, today announced the opening of the second round of its AiCubator corporate innovation accelerator initiative.

2021-09-20

AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections

Start of a pilot study with immunomodulator AIC649 for treatment of asymptomatic or mildly symptomatic COVID-19-patients to prevent more severe symptoms including respiratory failure that may develop with progression of the disease.

2021-09-17

AiCuris befürwortet und unterstützt die Nationale Allianz für Pandemie-Therapeutika (NA-PATH)

NA-PATH ist eine Initiative des Helmholtz-Zentrums für Infektionsforschung (HZI) und des Deutschen Zentrums für Infektionsforschung (DZIF), die einen Sektor-übergreifenden Ansatz vorschlägt, um auf zukünftige Pandemien durch virale Erreger vorbereitet zu sein.

2021-07-08

AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of herpes simplex virus infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

Start of pivotal phase 3 development with its proprietary lead compound pritelivir, a novel helicase-primase inhibitor, following encouraging phase 2 interim results achieved in the phase 2 part of its clinical phase 2/3 trial, PRIOH-1.

2021-05-25

AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the AiCuris Supervisory Board

The Supervisory Board appointed Dr. Stefan Oschmann as Chairman. He succeeds Helmut Jeggle, Chief Executive Officer of Salvia GmbH, who stepped down as planned from his role as Interim-Chairman of the initial Supervisory Board of AiCuris AG

The Powerhouse for Anti-infectives

Committed to making the difference

Fighting infectious diseases of the 21st century

Our innovative Pipeline

Expanding our Portfolio